Drug Trial Radar · NCT06127043
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Dec 4, 2023
Primary completion
Jan 2026
Study completion May 2026
Sponsor
- Lead sponsor
- AnaptysBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
Conditions
- Ulcerative Colitis
Interventions
RosnilimabDrug
PD-1 agonist antibody
PlaceboDrug
Administered via SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in modified Mayo Score (mMs) from Baseline to Week 12Time frame: Baseline to Week 12
Locations
100 sites in 15 countries. Site status is shown where the registry gives one.
AnaptysBio Investigational Site 10-115
Phoenix, Arizona
AnaptysBio Investigational Site 10-117
Garden Grove, California
AnaptysBio Investigational Site 10-112
Lancaster, California
AnaptysBio Investigational Site 10-129
Lancaster, California
AnaptysBio Investigational Site 10-108
San Jose, California
AnaptysBio Investigational Site 10-127
Brooksville, Florida
AnaptysBio Investigational Site 10-106
Miami, Florida
AnaptysBio Investigational Site 10-109
Miami Gardens, Florida
AnaptysBio Investigational Site 10-131
Orlando, Florida
AnaptysBio Investigational Site 10-123
Orlando, Florida
AnaptysBio Investigational Site 10-125
Tampa, Florida
AnaptysBio Investigational Site 10-122
Atlanta, Georgia
AnaptysBio Investigational Site 10-124
Oak Lawn, Illinois
AnaptysBio Investigational Site 10-118
Las Vegas, Nevada
AnaptysBio Investigational Site 10-133
Utica, New York
AnaptysBio Investigational Site 10-136
Cincinnati, Ohio
AnaptysBio Investigational Site 10-120
Norman, Oklahoma
AnaptysBio Investigational Site 10-103
Kingsport, Tennessee
AnaptysBio Investigational Site 10-104
Dallas, Texas
AnaptysBio Investigational Site 10-113
Garland, Texas
AnaptysBio Investigational Site 10-135
Georgetown, Texas
AnaptysBio Investigational Site 10-134
Lubbock, Texas
AnaptysBio Investigational Site 10-130
Southlake, Texas
AnaptysBio Investigational Site 10-132
Tyler, Texas
AnaptysBio Investigational Site 10-107
Seattle, Washington
AnaptysBio Investigational Site 12-101
Innsbruck, Austria
AnaptysBio Investigational Site 12-104
Salzburg, Austria
AnaptysBio Investigational Site 12-103
Sankt Pölten, Austria
AnaptysBio Investigational Site 12-102
Vienna, Austria
AnaptysBio Investigational Site 61-102
Sofia, Bulgaria
AnaptysBio Investigational Site 11-105
Calgary, Canada
AnaptysBio Investigational Site 11-102
London, Ontario, Canada
AnaptysBio Investigational Site 11-103
Montreal, Quebec, Canada
AnaptysBio Investigational Site 74-104
Rijeka, Croatia
AnaptysBio Investigational Site 74-101
Zagreb, Croatia
AnaptysBio Investigational Site 16-102
Nantes, France
AnaptysBio Investigational Site 16-103
Nantes, France
AnaptysBio Investigational Site 16-101
Tours, France
AnaptysBio Investigational Site 59-106
Tbilisi, Georgia
AnaptysBio Investigational Site 59-103
Tbilisi, Georgia
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.